Artiva Biotherapeutics (ARTV) Competitors $11.20 +0.32 (+2.94%) (As of 11/22/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends ARTV vs. REPL, VIR, LENZ, IMTX, AUTL, RLAY, AVXL, CRGX, CGEM, and TECXShould you be buying Artiva Biotherapeutics stock or one of its competitors? The main competitors of Artiva Biotherapeutics include Replimune Group (REPL), Vir Biotechnology (VIR), LENZ Therapeutics (LENZ), Immatics (IMTX), Autolus Therapeutics (AUTL), Relay Therapeutics (RLAY), Anavex Life Sciences (AVXL), CARGO Therapeutics (CRGX), Cullinan Therapeutics (CGEM), and Tectonic Therapeutic (TECX). These companies are all part of the "biological products, except diagnostic" industry. Artiva Biotherapeutics vs. Replimune Group Vir Biotechnology LENZ Therapeutics Immatics Autolus Therapeutics Relay Therapeutics Anavex Life Sciences CARGO Therapeutics Cullinan Therapeutics Tectonic Therapeutic Replimune Group (NASDAQ:REPL) and Artiva Biotherapeutics (NASDAQ:ARTV) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability, community ranking, valuation and media sentiment. Does the media favor REPL or ARTV? In the previous week, Replimune Group had 13 more articles in the media than Artiva Biotherapeutics. MarketBeat recorded 21 mentions for Replimune Group and 8 mentions for Artiva Biotherapeutics. Replimune Group's average media sentiment score of 0.44 beat Artiva Biotherapeutics' score of 0.36 indicating that Replimune Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Replimune Group 2 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Artiva Biotherapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals & insiders have more ownership in REPL or ARTV? 92.5% of Replimune Group shares are owned by institutional investors. 8.8% of Replimune Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Is REPL or ARTV more profitable? Artiva Biotherapeutics' return on equity of 0.00% beat Replimune Group's return on equity.Company Net Margins Return on Equity Return on Assets Replimune GroupN/A -53.12% -41.49% Artiva Biotherapeutics N/A N/A N/A Which has higher valuation & earnings, REPL or ARTV? Artiva Biotherapeutics has higher revenue and earnings than Replimune Group. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioReplimune GroupN/AN/A-$215.79M-$3.05-4.90Artiva Biotherapeutics$2.60M104.59N/AN/AN/A Do analysts rate REPL or ARTV? Replimune Group presently has a consensus target price of $17.00, indicating a potential upside of 13.86%. Artiva Biotherapeutics has a consensus target price of $21.25, indicating a potential upside of 89.73%. Given Artiva Biotherapeutics' higher possible upside, analysts plainly believe Artiva Biotherapeutics is more favorable than Replimune Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Replimune Group 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14Artiva Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community believe in REPL or ARTV? Replimune Group received 156 more outperform votes than Artiva Biotherapeutics when rated by MarketBeat users. However, 100.00% of users gave Artiva Biotherapeutics an outperform vote while only 63.32% of users gave Replimune Group an outperform vote. CompanyUnderperformOutperformReplimune GroupOutperform Votes16463.32% Underperform Votes9536.68% Artiva BiotherapeuticsOutperform Votes8100.00% Underperform VotesNo Votes SummaryReplimune Group beats Artiva Biotherapeutics on 8 of the 13 factors compared between the two stocks. Ad Crypto Swap Profits[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.Register for the FREE Workshop Now & get $10 in Bitcoin Get Artiva Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ARTV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARTV vs. The Competition Export to ExcelMetricArtiva BiotherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$272.04M$3.04B$5.38B$8.84BDividend YieldN/A1.91%5.13%4.09%P/E RatioN/A45.50105.0417.81Price / Sales104.59392.401,235.79158.52Price / CashN/A169.3840.3536.29Price / Book1.354.597.086.50Net IncomeN/A-$41.63M$119.58M$226.22M7 Day Performance11.33%2.61%2.25%4.03%1 Month Performance2.28%-2.47%-2.34%4.92%1 Year PerformanceN/A28.24%33.95%29.30% Artiva Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARTVArtiva BiotherapeuticsN/A$11.20+2.9%$21.25+89.7%N/A$272.04M$2.60M0.0081REPLReplimune Group4.1658 of 5 stars$14.93+35.1%$17.00+13.9%+45.1%$1.02BN/A-5.20210Analyst ForecastNews CoverageGap UpHigh Trading VolumeVIRVir Biotechnology2.8535 of 5 stars$7.12+2.4%$36.40+411.2%-27.6%$980.57M$86.18M-1.82587Analyst ForecastAnalyst RevisionLENZLENZ Therapeutics0.5935 of 5 stars$35.50+3.4%$35.40-0.3%N/A$976.25MN/A0.00N/APositive NewsIMTXImmatics2.0648 of 5 stars$7.59+0.1%$16.67+119.6%-7.3%$905.94M$58.44M-11.50260Analyst ForecastAnalyst RevisionAUTLAutolus Therapeutics3.5085 of 5 stars$2.94+3.5%$10.15+245.2%-34.4%$782.32M$10.09M-2.43330RLAYRelay Therapeutics3.3008 of 5 stars$4.75+2.4%$21.22+346.8%-41.1%$776.66M$10.01M-1.82304High Trading VolumeAVXLAnavex Life Sciences3.7579 of 5 stars$9.11+1.0%$40.00+339.1%+36.0%$772.49MN/A-18.2240Upcoming EarningsCRGXCARGO Therapeutics1.5402 of 5 stars$16.23+3.2%$30.33+86.9%+9.1%$747.07MN/A-3.69116CGEMCullinan Therapeutics2.0587 of 5 stars$12.54+2.6%$31.67+152.5%+47.9%$730.20M$18.94M-4.4230Analyst RevisionTECXTectonic Therapeutic3.4796 of 5 stars$48.10+7.2%$72.25+50.2%N/A$709.48MN/A-8.17120Analyst ForecastHigh Trading Volume Related Companies and Tools Related Companies REPL Alternatives VIR Alternatives LENZ Alternatives IMTX Alternatives AUTL Alternatives RLAY Alternatives AVXL Alternatives CRGX Alternatives CGEM Alternatives TECX Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ARTV) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Artiva Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Artiva Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
